{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:46:33Z","timestamp":1791618393884,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ejca.2015.04.007","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T17:30:05Z","timestamp":1430587805000},"page":"1243-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":214,"title":["FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer"],"prefix":"10.1016","volume":"51","author":[{"given":"C.","family":"Bokemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-H.","family":"K\u00f6hne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Klinkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Duecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"van Krieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.04.007_b0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0010","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0015","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0020","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2015.04.007_b0025","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","author":"Sorich","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2015.04.007_b0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1373\/clinchem.2003.024505","article-title":"Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis","volume":"50","author":"Chen","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2015.04.007_b0040","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.1133470100","article-title":"Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations","volume":"100","author":"Dressman","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2015.04.007_b0045","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2015.04.007_b0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1053\/j.gastro.2008.05.039","article-title":"Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients","volume":"135","author":"Diehl","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2015.04.007_b0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2015.04.007_b0060","article-title":"CALGB\/SWOG 80405: Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in untreated metastatic adenocarcinoma of the colon or rectum","author":"Lenz","year":"2014","journal-title":"ESMO"},{"key":"10.1016\/j.ejca.2015.04.007_b0065","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0070","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0080","first-page":"259","article-title":"Personalized cancer treatment and the myth of KRAS wild-type colon tumors","volume":"15","author":"Parsons","year":"2013","journal-title":"Discov Med"},{"key":"10.1016\/j.ejca.2015.04.007_b0085","article-title":"Clinical relevance of KRAS-mutated sub-clones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy","author":"Laurent-Puig","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2015.04.007_b0090","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/annonc\/mds620","article-title":"Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer","volume":"24","author":"Tougeron","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.04.007_b0095","doi-asserted-by":"crossref","unstructured":"Taly V, Laurent-Puig, P., Pekin, D., Doe J. Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management. American Association for Cancer Research Annual Meeting San Diego, CA, April 5\u20139, 2014: Abstr 2820.","DOI":"10.1158\/1538-7445.AM2014-2820"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915003111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915003111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T09:21:41Z","timestamp":1566638501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915003111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0959804915003111"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.04.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}